CAJ | 학술논문

套细胞淋巴瘤(MCL)是一种少见、独特的B细胞非霍奇金淋巴瘤(NHL)亚型.现有不少治疗MCL的药物和方案,均有一定疗效,但疗效维持时间短,不够理想.目前认为MCL是难以治愈的,预后不良.文章着重介绍了一种治疗MCL的新药替西罗莫司.该药是雷帕霉素的衍生物,它通过下调淋巴瘤的Cyclin D1和Ki-67,阻断细胞周期,诱导肿瘤缩小,抑制肿瘤生长.研究显示替西罗莫司能诱导MCL患者缓解和延长生存,特别对复发性或难治性MCL患者有一定疗效.另外,替西罗莫司与利妥昔单抗,或与其他化疗药物联合应用,能获得比单用替西罗莫司更好的效果.
투세포림파류(MCL)시일충소견、독특적B세포비곽기금림파류(NHL)아형.현유불소치료MCL적약물화방안,균유일정료효,단료효유지시간단,불구이상.목전인위MCL시난이치유적,예후불량.문장착중개소료일충치료MCL적신약체서라막사.해약시뢰파매소적연생물,타통과하조림파류적Cyclin D1화Ki-67,조단세포주기,유도종류축소,억제종류생장.연구현시체서라막사능유도MCL환자완해화연장생존,특별대복발성혹난치성MCL환자유일정료효.령외,체서라막사여리타석단항,혹여기타화료약물연합응용,능획득비단용체서라막사경호적효과.
Mantal cell lymphoma (MCL) is a rare and special type of non-Hodgkin lymphoma.MCL is classified as an aggressive variety of lymphoma and yet it sometimes behaves as an indolent lymphoma.Although the first-line therapy of MCL is highly effective,but it is incurable through conventional chemotherapy.Patients with MCL have a poor prognosis.This review focus on a new therapeutic approach,mammalian target of rapamycin (mTOR) inhibitor.Temsirolimus,a derivation of rapamycin,in MCL cell lines inhibited mTOR.Temsirolimus could inhibits tumor cell proliferation through cell cycle arrest and able to down-regulation of cyclin D1 and Ki-67 in lymphomacell.Clinical trials showed that temsirolimus induced patients with MCL response rate and a prolong progression-free survival.In addition,preclinical studies demonstrated the use of a combination of temsirolimus with monoclonal antibodies or conventional chemotherapy to improve the efficacy of single agent use.Altogether,temsirolimus shows promising results in the therapy of patients with heavily MCL,and especially responses in chemotherapy refractory patients,providing a novel approaches to treatment of MCL.